Javara, a leading integrated research organization (IRO) that delivers clinical trials at the point of care through strategic partnerships with healthcare organizations, announced it has secured significant growth investment in Series C funding from existing and new community-based investors.
Launched in 2018, Javara was built with a vision to revolutionize the industry by accelerating access to research for patients, biopharma companies, and healthcare organizations alike. Founders Jennifer Byrne, Linda McCarty, and Amanda Wright say this funding is an essential next step in advancing their mission.
Javara’s current access includes 5+ million patients across seven states. The organization now faces the opportunity to double both patient and physician reach, as well as develop new areas of therapeutic excellence that parallel current primary public health concerns and the rapid evolution of the clinical trials industry.
How the funding will be used: This funding will support the expansion of both current and new healthcare partnerships, enabling the company to grow into new therapeutic specialties, such as Oncology, CNS, and Neurology, through localized clinical research collaborations that increase patient access and expand the geographic footprint.
Advisors: Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan advised Javara on the Series C funding round. And Crosstree Capital Partners acted as an advisor to Javara.
KEY QUOTES:
“We are extremely grateful for the privilege and opportunity this funding secures as we move into an accelerated growth era for Javara. The support of a broadened group of community-based investors will amplify our impact greatly as we work to deliver community-based clinical trial access and education for more patients across the nation.”
Javara Founder and CEO Jennifer Byrne
